A. M. Parsadanyan

A. M. Parsadanyan

Auto-generated profile, based on publicly available information

A. M. Parsadanyan

Surgut State University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2023 in Creative surgery and oncology
Verified
Journal Article
Open access
PDF file
ASA. I. Sherifova
A. I. Sherifova
APA. M. Parsadanyan
A. M. Parsadanyan
The present paper reviews current publications of Russian and foreign authors addressing the issues of liver pathology and associated consequences. Primary liver cancer is a malignant tumor originated from hepatocytes and epithelium of the biliary duct. It differs from other liver pathologies by rapid progression and low life expectancy of patients. The morphology of cancer and its carcinogenesis is particularly considered. The paper describes the carcinogenesis of liver cancer in detail. Numerous scientific papers consider liver cancer as a global health issue due to the late diagnosis and, consequently, the limited treatment options for patients with this disease. The analysis of recent publications revealed that the incidence of this pathology tends to increase worldwide. According to the available data provided by different experts who study cancer globally, about 906 thousand new cases of liver cancer are registered annually and the number of patients is expected to exceed 1.4 million by 2040. In the conclusion, the present paper briefly observes the reasons of the late diagnosis of liver cancer and its consequences.

1 January 2023 in Proceedings in Cybernetics
Verified
Journal Article
Closed access
APA. I. Pakhtusov
A. I. Pakhtusov
ELE. V. Logareva
E. V. Logareva
APA. M. Parsadanyan
A. M. Parsadanyan
AKA. E. Kasparova
A. E. Kasparova
DFDmitriy Alekseevich Fedorov
Dmitriy Alekseevich Fedorov
KAKhanty-Mansiysk Khanty-Mansi State Medical Academy
Khanty-Mansiysk Khanty-Mansi State Medical Academy

30 June 2022 in Ulyanovsk Medico-biological Journal
Verified
Journal Article
Closed access
MIMaksim Dmitrievich Ivanov
Maksim Dmitrievich Ivanov
APArarat Mikichovich Parsadanyan
Ararat Mikichovich Parsadanyan
AKAnzhelika Eduardovna Kasparova
Anzhelika Eduardovna Kasparova
The aim of the study is to analyze the literature available, to examine bariatric surgery as a treatment for people with metabolic syndrome (a risk factor for atypical endometrial hyperplasia), and to evaluate bariatric surgery significance in reducing endometrial cancer incidence. Materials and Methods. The authors scanned the platforms Springer, Pubmed, IFSO, and Google Scholar using such key words as metabolic syndrome, simple and atypical endometrial hyperplasia, endometrial cancer and bariatric surgery, methods for the metabolic syndrome correction in patients with endometrial cancer, effects of bariatric surgery on endometrial cancer, treatment of metabolic syndrome in patients-at-risk for endometrial cancer. The authors examined the articles published in English and Russian no longer than 10 years ago. Results. Metabolic syndrome is a risk factor for endometrial cancer and comorbidity. It expands the bariatric surgery alternatives for patients with Class 1 and Class 2 obesity.

17 November 2026 in Medical alphabet
Verified
Journal Article
Closed access
AMA. A. Mordovskii
A. A. Mordovskii
AAA. А. Aksarin
A. А. Aksarin
APA. M. Parsadanyan
A. M. Parsadanyan
PTP. P. Troyan
P. P. Troyan
Relevance. The article presents the results of a comprehensive analysis of clinical, epidemiological, morphological, and anamnestic characteristics of 316 patients with non-small cell lung cancer (NSCLC), residents of the Khanty-Mansi Autonomous district – Yugra, in whom molecular genetic alterations were identified. Objective. To conduct a comprehensive analysis of clinical, morphological, demographic, and anamnestic (smoking history) parameters and duration of residence in the region in patients with NSCLC who have confirmed molecular genetic alterations, as well as to assess their differences from a reference group of patients in whom driver mutations have not been detected, in the territory of the Khanty-Mansi Autonomous district – Yugra. Materials and methods. The study included 316 cases of NSCLC registered at the oncology center based at the Surgut District Clinical Hospital during 2020–2023. All patients with morphologically verified NSCLC, regardless of stage and histological subtype, underwent testing of a panel of genetic markers including EGFR, ALK, ROS1, BRAF, ERBB2 (HER2), KRAS, MET, RET, NTRK1/2/3, and PD-L1 expression level was determined (<1%, 1–49%, ≥50%). Molecular genetic testing of surgical and biopsy material was performed in two consecutive stages using polymerase chain reaction (PCR) and nextgeneration sequencing (NGS) methods. Immunohistochemical analysis of PD-L1 expression was performed using validated test systems: clone 22C3 (DAKO) and clone SP263 (VENTANA). Morphological verification of the diagnosis was based on histopathological examination, and the extent of the process was assessed according to the 8th edition of the TNM system. For each patient, the following parameters were recorded: sex, age, smoking history, stage, tumor topography, histological subtype of NSCLC, PD-L1 expression, and continuous duration (years) of residence in KhMAO-Yugra before diagnosis. Depending on the presence or absence of molecular genetic alterations, two groups were formed: the main group (126 patients with driver mutations) and the comparison group (190 patients without them). To assess the prevalence of smoking in the general population of lung cancer patients (all histological subtypes) in KhMAO-Yugra, an additional retrospective analysis of the regional cancer registry database for the period from 2011 to 2022 (2018 cases) was performed. Medical records contained information on smoking status (current, former, or never smokers). These data were used for a comparative assessment of smoking frequency in the general cohort of lung cancer patients in the region and in the sample of patients who underwent molecular genetic testing. Statistical processing methods were used. Conclusions. The study showed that genetic aberrations are most common in adenocarcinoma (34% of cases), whereas in other histotypes their proportion is only 6%. In the mutation structure, alterations in EGFR (15%) and KRAS (14%) genes predominate; ALK rearrangements (5%), HER2 amplification (3%), ROS1 rearrangements (2%), and BRAF mutations (1%) are less frequently recorded. Significant associations were established: in non-smoking patients and in adenocarcinoma, the risk of detecting EGFR, KRAS mutations and ALK rearrangement is significantly higher, whereas long-term residence in the region (≥30 years) is associated with a lower probability of detecting EGFR mutations and ALK rearrangement. PD-L1 expression status did not affect the frequency of the studied driver mutations. The obtained data indicate regional features of the molecular profile of NSCLC in Yugra, which substantiates the need to adapt diagnostic algorithms and therapeutic approaches taking into account local clinical and epidemiological conditions to improve the effectiveness of drug provision and personalize treatment.